erlotinib hydrochloride has been researched along with etoposide in 11 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (etoposide) | Trials (etoposide) | Recent Studies (post-2010) (etoposide) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 18,306 | 3,693 | 4,900 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | etoposide (IC50) |
|---|---|---|---|
| nuclear receptor coactivator 1 isoform 1 [Homo sapiens] | Homo sapiens (human) | 1.153 | |
| nuclear receptor coactivator 3 isoform a | Homo sapiens (human) | 1.4284 | |
| Polyunsaturated fatty acid lipoxygenase ALOX15 | Oryctolagus cuniculus (rabbit) | 3.187 | |
| Caspase-3 | Homo sapiens (human) | 1 | |
| DNA topoisomerase 2-beta | Homo sapiens (human) | 0.4299 | |
| Solute carrier organic anion transporter family member 1B3 | Homo sapiens (human) | 4.18 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 6 (54.55) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Iwashige, A; Kagami, S; Tsukada, J; Uramoto, H | 1 |
| Choong, NW; Dancey, JE; Grushko, T; Haraf, DJ; Hoffman, PC; Kozloff, M; Lester, E; Lin, S; Mauer, AM; Olopade, OI; Salgia, R; Szeto, L; Vokes, EE | 1 |
| Becker, M; Fichtner, I; Hammer, S; Hoffmann, J; Merk, J; Rolff, J; Sommer, A; Soong, R | 1 |
| Abonyi-Tóth, Z; Katona, L; Kovács, G; Moldvay, J; Rokszin, G | 1 |
| Yano, S | 1 |
| Costa, DB; Desai, NV; Folch, E; Gangadharan, SP; Huberman, MS; Karp, RS; Kent, MS; Le, X; Majid, A; Rangachari, D; VanderLaan, PA | 1 |
| Bouffet, E; Bowers, DC; Foley, MA; Gill, SC; Horan, J; Jakacki, RI; Kieran, MW; Wang, J; Zacharoulis, S | 1 |
| Costa, JC; Grauslund, M; Melchior, LC; Santoni-Rugiu, E; Sørensen, JB; Urbanska, EM | 1 |
| Celik, B; Demirag, MK; Elmali, M; Gulel, O | 1 |
| Feng, M; Li, Q; Liao, W; Qian, Z; Wen, F; Wu, Q; Yang, Y | 1 |
| Li, S; Li, Z; Liu, S; Wang, Z; Zhao, F | 1 |
2 review(s) available for erlotinib hydrochloride and etoposide
| Article | Year |
|---|---|
[Chemotherapy for lung cancer patients].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Erlotinib Hydrochloride; Etoposide; Evidence-Based Medicine; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Taxoids | 2006 |
[Programs for continuing medical education: B session; 4. Progress in lung cancer therapy].
Topics: Anaplastic Lymphoma Kinase; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cisplatin; Crizotinib; Drug Discovery; Education, Medical, Continuing; Erlotinib Hydrochloride; Etoposide; Gefitinib; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Molecular Targeted Therapy; Pemetrexed; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Small Cell Lung Carcinoma | 2014 |
2 trial(s) available for erlotinib hydrochloride and etoposide
| Article | Year |
|---|---|
Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Etoposide; Female; Gene Amplification; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Survival Rate; Taxoids | 2008 |
Single-agent erlotinib versus oral etoposide in patients with recurrent or refractory pediatric ependymoma: a randomized open-label study.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Phytogenic; Child; Child, Preschool; Disease-Free Survival; Ependymoma; Erlotinib Hydrochloride; Etoposide; Female; Humans; Infant; Male; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Treatment Outcome; Young Adult | 2016 |
7 other study(ies) available for erlotinib hydrochloride and etoposide
| Article | Year |
|---|---|
Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.
Topics: Adenocarcinoma; Adult; Aged; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Etoposide; Female; Gemcitabine; Gene Expression Profiling; Genes, ras; Humans; Immunoblotting; Lung Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Middle Aged; Mutation; Oligonucleotide Array Sequence Analysis; Paclitaxel; Polymerase Chain Reaction; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents; Small Cell Lung Carcinoma; Tumor Suppressor Protein p53; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2008 |
[Analysis of drug therapy of lung cancer in Hungary].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Databases, Factual; Deoxycytidine; Docetaxel; Drug Administration Schedule; Erlotinib Hydrochloride; Etoposide; Gemcitabine; Glutamates; Guanine; Humans; Hungary; Inpatients; Insurance, Health; Lung Neoplasms; Paclitaxel; Pemetrexed; Prescription Drugs; Quinazolines; Retrospective Studies; Taxoids; Topotecan | 2013 |
De novo pulmonary small cell carcinomas and large cell neuroendocrine carcinomas harboring EGFR mutations: Lack of response to EGFR inhibitors.
Topics: Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Neuroendocrine; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Etoposide; Fatal Outcome; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Radiography; Small Cell Lung Carcinoma | 2015 |
Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation.
Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Etoposide; Exons; Genetic Heterogeneity; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Receptor, Fibroblast Growth Factor, Type 3 | 2017 |
A rare complication of metastatic lung disease treatment.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Erlotinib Hydrochloride; Etoposide; Humans; Lung Neoplasms; Male; Neoplasm Metastasis; Pericardium; Tomography, X-Ray Computed; Tongue Neoplasms | 2017 |
Study on the prognosis, immune and drug resistance of m6A-related genes in lung cancer.
Topics: Adenosine; Afatinib; Crizotinib; Dasatinib; Drug Resistance; Erlotinib Hydrochloride; Etoposide; Humans; Lapatinib; Lung Neoplasms; Tumor Microenvironment; Ubiquitin-Protein Ligases | 2022 |
Identifying a lactic acid metabolism-related gene signature contributes to predicting prognosis, immunotherapy efficacy, and tumor microenvironment of lung adenocarcinoma.
Topics: Adenocarcinoma of Lung; Erlotinib Hydrochloride; Etoposide; Gefitinib; Humans; Immunologic Factors; Immunotherapy; Lactic Acid; Lung Neoplasms; Prognosis; Reproducibility of Results; Tumor Microenvironment | 2022 |